Filing Details

Accession Number:
0001104659-24-099838
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-09-13 16:35:19
Reporting Period:
2024-09-11
Accepted Time:
2024-09-13 16:35:19
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1377121 Protagonist Therapeutics Inc PTGX Pharmaceutical Preparations (2834) 980505495
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1921163 Asif Ali C/O Protagonist Therapeutics, Inc.
7707 Gateway Blvd., Suite 140
Newark CA 94560-1160
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-09-11 2,203 $44.59 34,960 No 4 S Direct
Common Stock Acquisiton 2024-09-11 6,000 $19.19 40,960 No 4 M Direct
Common Stock Acquisiton 2024-09-11 6,000 $12.17 46,960 No 4 M Direct
Common Stock Disposition 2024-09-11 12,000 $44.47 34,960 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2024-09-11 6,000 $0.00 6,000 $19.19
Common Stock Stock Option (right to buy) Disposition 2024-09-11 6,000 $0.00 6,000 $12.17
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
76,500 2032-04-18 No 4 M Direct
45,750 2033-01-15 No 4 M Direct
Footnotes
  1. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $44.43 to $44.64. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  2. The stock option was granted to the Reporting Person on April 18, 2022, one quarter vested on April 18, 2023 and the remaining three quarters vest in equal monthly installments through April 18, 2026, subject to the Reporting Person's continued service to the Issuer.
  3. The stock option was granted to the Reporting Person on January 16, 2023 and vests in 48 equal monthly installments following the date of grant, subject to the Reporting Person's continued service to the Issuer.